{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:39:06Z","timestamp":1784907546420,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-breast-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clbc.2024.01.018","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T19:58:10Z","timestamp":1709927890000},"page":"e195-e202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Efficiency and Toxicity Of Anlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study"],"prefix":"10.1016","volume":"24","author":[{"given":"Xi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6521-702X","authenticated-orcid":false,"given":"Xinyu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peizhuo","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafeng","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyou","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youhuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2024.01.018_bib0001","unstructured":"Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD. Accessed December 13, 2022. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2014\/."},{"issue":"8","key":"10.1016\/j.clbc.2024.01.018_bib0002","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2024.01.018_bib0003","doi-asserted-by":"crossref","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","article-title":"NCCN clinical practice guidelines in oncology: breast cancer, version 5. 2020","volume":"18","author":"Gradishar","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.clbc.2024.01.018_bib0004","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","article-title":"Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019","volume":"30","author":"Burstein","year":"2019","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.clbc.2024.01.018_bib0005","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/cncr.29348","article-title":"Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States","volume":"121","author":"Mougalian","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2024.01.018_bib0006","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"10.1016\/j.clbc.2024.01.018_bib0007","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41571-019-0181-9","article-title":"Vessel co-option in cancer","volume":"16","author":"Kuczynski","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clbc.2024.01.018_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.clbc.2024.01.018_bib0009","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1158\/1078-0432.CCR-12-3029","article-title":"Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial","volume":"19","author":"Schneider","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.clbc.2024.01.018_bib0010","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jsps.2011.12.001","article-title":"The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab)","volume":"20","author":"Sasich","year":"2012","journal-title":"Saudi Pharm J"},{"issue":"1","key":"10.1016\/j.clbc.2024.01.018_bib0011","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2024.01.018_bib0012","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","article-title":"Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors","volume":"23","author":"Strumberg","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2024.01.018_bib0013","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1158\/1078-0432.CCR-11-1900","article-title":"A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors","volume":"18","author":"Mross","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.clbc.2024.01.018_bib0014","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2174\/156802612803531333","article-title":"Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib","volume":"12","author":"Erdem","year":"2012","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"10.1016\/j.clbc.2024.01.018_bib0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clbc.2024.01.018_bib0016","unstructured":"RECIST 1.1\u2014standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. Accessed: January 1, 2023. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/27237360\/"},{"issue":"28","key":"10.1016\/j.clbc.2024.01.018_bib0017","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2024.01.018_bib0018","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0197-2456(89)90035-4","article-title":"Multicenter investigator-initiated trials","volume":"10","author":"Lenfant","year":"1989","journal-title":"Control Clin Trials"},{"issue":"1","key":"10.1016\/j.clbc.2024.01.018_bib0019","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.soc.2022.07.003","article-title":"The development of investigator-initiated clinical trials in surgical oncology","volume":"32","author":"McDonald","year":"2023","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.clbc.2024.01.018_bib0020","unstructured":"Declaration of Helsinki Accessed January 1, 2023. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/14194486\/"},{"issue":"5","key":"10.1016\/j.clbc.2024.01.018_bib0021","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.tranon.2016.07.002","article-title":"Angiogenesis and antiangiogenesis in triple-negative breast cancer","volume":"9","author":"Ribatti","year":"2016","journal-title":"Transl Oncol"},{"issue":"32","key":"10.1016\/j.clbc.2024.01.018_bib0022","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","volume":"29","author":"Brufsky","year":"2011","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clbc.2024.01.018_bib0023","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2024.01.018_bib0024","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2024.01.018_bib0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.clbc.2011.03.005","article-title":"Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial","volume":"11","author":"Robert","year":"2011","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2024.01.018_bib0026","first-page":"161","article-title":"Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy","volume":"1846","author":"Gacche","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.clbc.2024.01.018_bib0027","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ctrv.2011.08.001","article-title":"Docetaxel combined with targeted therapies in metastatic breast cancer","volume":"38","author":"Cortes","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"22","key":"10.1016\/j.clbc.2024.01.018_bib0028","first-page":"3986","article-title":"Efficacy and safety of chemotherapy combined with anrotinib in the treatment of advanced triple-negative breast cancer","volume":"27","author":"Zhang","year":"2019","journal-title":"Modern Oncol Med"},{"issue":"1","key":"10.1016\/j.clbc.2024.01.018_bib0029","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2024.01.018_bib0030","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/ijc.28829","article-title":"Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"135","author":"Hu","year":"2014","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.clbc.2024.01.018_bib0031","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1634\/theoncologist.2010-0081","article-title":"A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium","volume":"15","author":"Taylor","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2024.01.018_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.838133","article-title":"Targeting angiogenesis in breast cancer: current evidence and future perspectives of novel anti-angiogenic approaches","volume":"13","author":"Ayoub","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clbc.2024.01.018_bib0033","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.2147\/CMAR.S364125","article-title":"The efficacy and safety of anlotinib in extensive-stage small cell lung cancer: a multicenter real-world study","volume":"14","author":"Zheng","year":"2022","journal-title":"CMAR"},{"issue":"2","key":"10.1016\/j.clbc.2024.01.018_bib0034","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s10637-021-01179-2","article-title":"A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum\/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer","volume":"40","author":"Huang","year":"2022","journal-title":"Invest New Drugs"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924000284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924000284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T16:36:12Z","timestamp":1742229372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820924000284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1526820924000284"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2024.01.018","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Efficiency and Toxicity Of Anlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2024.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}